Steriles Leader


A Range Of Drug Product

Cenexi is a CDMO offering fill and finish of liquid and lyophilized sterile dosage forms, and manufacturing and integrated packaging for oral solid and liquid products. It manufactures three billion tablets a year and one billion capsules, along with hormone solid forms, suppositories and syrups. Cenexi has cytotoxic capabilities and has earned a strong reputation for oncology products in prefilled syringes and liquid or lyophilized vials. With more than 25 years of experience, production is divided across facilities in France and Belgium.

Quick Links

Thought Leadership

Pharma's Almanac

Not all CDMOs will be direct competitors, but there will inevitably be dozens making similar claims in marketing

Standing Out In A Competitive Market

Cenexi has a robust CDMO business with the range of drug product manufacturing it offers, as well as formulation, analytical development, and regulatory support. It brings 25 years of know-how and innovation, and capabilities in steriles and oncology products are aligned with market trends and demand. The fact is that all CDMOs face competition in a heavily regulated market, where hundreds of companies provide similar services. Not all CDMOs will be direct competitors, but there are inevitably dozens that will similar claims in their marketing.

Optimizing Opportunities

The challenge for any CDMO is how to optimize its chances firstly of being on the radar of companies seeking services, and consequently being in with a chance of being shortlisted and evaluated further, when direct dialogue influences the chance of selection. We encourage clients to engage in research to develop marketing and thought leadership that promotes the company’s strengths but, equally importantly, resonates with trend in audience-identified needs. This is what Cenexi did in updating its brand.

Signature Attraction

Cenexi offers a broad range of drug product manufacturing but its sterile oncology capabilities are a halo attraction that succeeds in focusing attention on the brand. Key art was developed that merged photography of finished dosage forms with technical line drawings, with prominence for sterile forms. A vibrant color palette adds to the potential for easy brand recall. The aesthetic complements Cenexi’s ability to talk about its state-of-the-art technologies and track record of innovation – all differentiating messages.

Further Expansion

In January 2017, Cenexi announced it was acquiring a manufacturing site located in Hérouville-Saint-Clair, France from Schering-Plough, the French subsidiary of Merck Sharp & Dohme. This site provides Cenexi with additional capacity, notably in sterile injectables, helping to reinforce its position as a market leader in this space.